Nirvana Life Sciences Inc.
NIRVF
$0.08
$0.080.00%
OTC PK
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.99% | 3.98% | -54.26% | -58.79% | -70.10% |
| Depreciation & Amortization | -- | -291.11% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.99% | -20.36% | -63.39% | -64.27% | -76.85% |
| Operating Income | 7.99% | 20.36% | 63.39% | 64.27% | 76.85% |
| Income Before Tax | 35.05% | 53.55% | 68.19% | 63.88% | 84.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.05% | 53.55% | 68.19% | 63.88% | 84.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 100.00% | -350.00% | -84.62% | -33.33% | -125.00% |
| Net Income | 35.21% | 53.34% | 68.05% | 63.87% | 84.89% |
| EBIT | 7.99% | 20.36% | 63.39% | 64.27% | 76.85% |
| EBITDA | -- | 20.15% | 65.19% | 61.46% | 76.36% |
| EPS Basic | 85.88% | 59.21% | 68.06% | 63.81% | 86.80% |
| Normalized Basic EPS | 81.13% | 25.84% | 67.86% | 63.75% | 87.76% |
| EPS Diluted | 85.88% | 59.21% | 68.06% | 63.81% | 86.80% |
| Normalized Diluted EPS | 81.13% | 25.84% | 67.86% | 63.75% | 87.76% |
| Average Basic Shares Outstanding | 373.19% | 14.46% | 0.00% | 0.00% | 14.75% |
| Average Diluted Shares Outstanding | 373.19% | 14.46% | 0.00% | 0.00% | 14.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |